Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients
Status:
Withdrawn
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Cancer patients with very difficult to control symptoms at the Abbotsford (AC) and Fraser
Valley (FVC) Cancer Centers are referred and admitted to the Tertiary Palliative Care Units
at the Abbotsford Regional Hospital and Cancer Center(ARHCC). For symptom management,
patients are sometimes given midazolam continuously through a needle placed underneath the
skin. While effective in symptom management, midazolam can be sedating, leaving patients
unable to interact with loved ones in their last days.
This study is a pilot project. Before proceeding to a full-scale study, a "pilot study" or
"feasibility study" is often carried out first to test the design of a study, the likelihood
of successful recruitment or the acceptability of the intervention to potential subjects. The
basic idea is to find out whether it will be practical to proceed to a larger study that will
include more subjects. This type of study involves only a small number of subjects and
therefore the results can only be used as a guide for further larger studies.
The investigators also will determine whether palliative care cancer patients taking a
medication called dexmedetomidine would have improved rousability (more easily and fully
awakened) and symptom control (pain, shortness of breath, nausea or confusion) compared with
those taking standard of care which is receiving the medication midazolam. The use of
dexmedetomidine in other clinical situations (in the Operating Room or Intensive Care Unit
where the patient can still respond to the doctor) has been shown to be effective in symptom
control and to provide a better degree of rousability to patients but has not been well
studied in the palliative care environment.